» Articles » PMID: 34716495

A Simple "signal Off-on" Fluorescence Nanoplatform for the Label-free Quantification of Exosome-derived MicroRNA-21 in Lung Cancer Plasma

Overview
Journal Mikrochim Acta
Specialties Biotechnology
Chemistry
Date 2021 Oct 30
PMID 34716495
Authors
Affiliations
Soon will be listed here.
Abstract

A simple nanoplatform based on molybdenum disulfide (MoS) nanosheets, a fluorescence quencher (signal off), and a hybridization chain reaction (HCR) signal amplification (signal on) used for the enzyme-free, label-free, and low-background signal quantification of microRNA-21 in plasma exosome is reported. According to the sequence of microRNA-21, carboxy-fluorescein (FAM)-labeled hybridization probe 1 (FAM-H1) and hybridization probes 2 (FAM-H2) were designed with excitation maxima at 488 nm and emission maxima at 518 nm. MoS nanosheets could adsorb FAM-H1 and FAM-H2 and quenched their fluorescence signals to reduce the background signal. However, HCR was triggered when microRNA-21 was present. Consequently, HCR products containing a large number of FAM fluorophores can emit a strong fluorescence at 518 nm and could realize the detection of microRNA-21 as low as 6 pmol/L and had a wide linear relation of 0.01-25 nmol/L. This assay has the ability of single-base mismatch recognition and could identify microRNA-21 with high specificity. Most importantly, this approach was successfully applied to the detection of plasma exosomal microRNA-21 in patients with lung cancer, and it is proposed that other targets can also be detected by changing the FAM-H1 and FAM-H2 corresponding to the target sequence. Thus, a novel, hands-on strategy for liquid biopsy was proposed and has a potential application value in the early diagnosis of lung cancer.

Citing Articles

Review of microRNA detection workflows from liquid biopsy for disease diagnostics.

Naranbat D, Herdes E, Tapinos N, Tripathi A Expert Rev Mol Med. 2025; 27:e11.

PMID: 39911053 PMC: 11879380. DOI: 10.1017/erm.2025.2.

References
1.
Terlizzi M, Colarusso C, Pinto A, Sorrentino R . Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 2019; 202:140-148. DOI: 10.1016/j.pharmthera.2019.06.005. View

2.
Mashouri L, Yousefi H, Aref A, Ahadi A, Molaei F, Alahari S . Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019; 18(1):75. PMC: 6444571. DOI: 10.1186/s12943-019-0991-5. View

3.
Oliveto S, Mancino M, Manfrini N, Biffo S . Role of microRNAs in translation regulation and cancer. World J Biol Chem. 2017; 8(1):45-56. PMC: 5329714. DOI: 10.4331/wjbc.v8.i1.45. View

4.
Sanz-Rubio D, Martin-Burriel I, Gil A, Cubero P, Forner M, Khalyfa A . Stability of Circulating Exosomal miRNAs in Healthy Subjects. Sci Rep. 2018; 8(1):10306. PMC: 6037782. DOI: 10.1038/s41598-018-28748-5. View

5.
Dejima H, Iinuma H, Kanaoka R, Matsutani N, Kawamura M . Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 2017; 13(3):1256-1263. PMC: 5403401. DOI: 10.3892/ol.2017.5569. View